title: [Healing and targeted therapies: Management in perioperative period?].
abstract: BACKGROUND
  In the era of new-targeted therapies and neoadjuvant strategies, this article highlights the role of angiogenesis in the process of physiological wound healing with a review of literature about parietal complications under anti-angiogenic therapies.
  
  
  METHODS
  Research on Medline was carried out using the terms renal cell carcinoma, angiogenesis, wound healing, targeted therapies, and complications.
  
  
  RESULTS
  The frequency of these complications varies between 5 and 50% in recent series. These results depend on half-lives of each drug and perioperative management (before and after surgical procedure).
  
  
  CONCLUSIONS
  In the absence of current recommendations, it is advised to stop bevacizumab at least five weeks before a surgical intervention and to take it back 4 weeks later. For the tyrosine kinase inhibitors, the treatment can be stopped 24-48 hours before the surgery and taken back 3-4 weeks later. Finally, for the mTOR inhibitors, it is advised to stop the treatment 7-10 days before and to take back it at least 3 weeks later.
authors.affiliation: Service d'urologie, hôpital Cochin, université René-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. gg_pignot@yahoo.fr
authors.forename: G
authors.initials: G
authors.lastname: Pignot
authors.forename: T
authors.initials: T
authors.lastname: Lebret
authors.forename: D
authors.initials: D
authors.lastname: Chekulaev
authors.forename: M
authors.initials: M
authors.lastname: Peyromaure
authors.forename: D
authors.initials: D
authors.lastname: Saighi
authors.forename: T
authors.initials: T
authors.lastname: Flam
authors.forename: D
authors.initials: D
authors.lastname: Amsellem-Ouazana
authors.forename: B
authors.initials: B
authors.lastname: Debre
authors.forename: M
authors.initials: M
authors.lastname: Zerbib
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D018919:Neovascularization, Physiologic; D059035:Perioperative Period; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors